Where the 33 Times Stronger THCP Claim Came From

Strange but True · Episode 6 of 7

THCP is 33 times stronger. That sentence travels well because it sounds simple, dramatic, and conveniently mathematical. The trouble starts with the word stronger: stronger at doing what, in which test, compared with which number?

The famous comparison has a real research source. It does not establish that a person gets a high that is thirty-three times greater. Keeping those two statements separate is the entire point of this article.

THCP vs THC: where the 33-times number came from

Cinzia Citti and colleagues published a THCP discovery paper in Scientific Reports in December 2019. The researchers identified and characterized the compound and studied its interaction with cannabinoid receptors. They also conducted behavioral tests in mice.

For the CB1 receptor, the paper reports a THCP binding-affinity value, called Ki, of 1.2 nanomolar. It compares that with a THC Ki value of 40 nanomolar reported in the literature. Dividing 40 by 1.2 gives approximately 33.3, the numerical basis of the widely repeated comparison.

That is a receptor-binding comparison under a specified research framework. The values have a measurement name, units, and a comparison source. Remove those details, and the number begins to sound like something the paper did not directly measure.

THCP binding affinity vs human effects

Binding affinity concerns the interaction of a molecule with a receptor in the test. Ki is a parameter used to describe that interaction; a lower value in this comparison indicates higher affinity. It is not a rating of a person’s subjective experience.

Think about comparing two keys in a lock test. A result about how they interact with the lock does not, by itself, tell you how an entire building operates. The analogy is imperfect, as all biology analogies are, but it keeps the scale of the question visible.

The researchers used human receptor material in a laboratory assay. The word human therefore identifies the receptor studied. It does not mean human participants described a thirty-three-fold difference in intoxication. A human-related laboratory component and a human-experience trial are different study designs.

The mouse tests answer another kind of question

The paper also investigated responses in mice. Those animal tests are part of the original research and can help scientists examine biological activity. They are not people assigning numbers to their experiences, and they cannot be renamed a controlled human comparison because a caption prefers that version.

The distinction is particularly important with a catchy ratio. A receptor result, an animal response, and a human subjective outcome can all be scientifically interesting. They are still separate endpoints. Evidence from one endpoint does not supply an exact numerical answer for another.

Our guide to internet cannabis claims explores that measurement swap: keep the original number, change what it supposedly measures, and a technically sourced statement becomes misleading.

How the viral sentence changes the claim

The careful sentence identifies a higher binding affinity at CB1 in the reported comparison. The viral sentence often replaces binding affinity with stronger, and a reader may understand stronger as a quantified human high. That is an extra inference.

To establish an exact human-experience ratio, research would need an appropriate human comparison, defined outcomes, and evidence supporting that ratio. The discovery paper does not provide that conclusion. Repeating its citation cannot fill in a study design it did not contain.

This is not a claim that THCP lacks biological activity or that the binding result is meaningless. It is a narrower point: the paper supports its reported measurements, while an exact multiplier for a person’s experience remains unsupported by that number.

A product label cannot inherit the whole experiment

A paper about a characterized compound is not automatically a test of a retail product that mentions the compound. Composition, identification, and the product’s connection to an actual analysis would require their own evidence.

That matters even before discussing effects. Seeing THCP printed in a caption does not establish a particular amount, a verified compound identity, or the complete mixture in an item. A scientific discovery and a later marketing phrase operate at different levels of specificity.

Our cannabis myths feature looks at how names and familiar claims can gain more authority than the evidence behind them. The same habit applies to a number with a paper attached.

The answer to remember

The THCP thirty-three-times claim originates in a 2019 receptor-binding comparison. It describes an affinity relationship, including a THC reference value from earlier literature. It does not quantify a thirty-three-fold human high or validate a particular consumer product.

The science is interesting without changing its unit of meaning. When someone repeats the number, ask what was measured. That short question gets you closer to the research than another confident repetition of stronger.

Sources and further reading

• Citti and colleagues: THCP discovery paper, Scientific Reports, 2019
• Original open-access paper PDF, including receptor assay and mouse-test methods

Series cover: original AI-assisted editorial illustration for Trap Snap LA. Photographs carry their own credits.

More questions about THCP’s receptor-binding comparison

What does THCP stand for?

The discovery paper names the compound tetrahydrocannabiphorol. Its name identifies a characterized cannabinoid, not a strength rating for a retail product. The original discovery paper.

How is THCP’s molecular structure different from THC?

The paper describes a seven-carbon alkyl side chain for THCP, compared with the familiar five-carbon chain in THC. That structural distinction is separate from a quantified human-experience claim. Citti and colleagues’ structural analysis.

What does Ki mean in the THCP paper?

Ki is a binding-affinity parameter in the reported receptor assay. In the cited comparison, a lower value indicates stronger affinity. It does not measure how high a participant felt. The original receptor-assay methods.

Did the THCP discovery study give THCP to human participants?

No human subjective-effects trial is reported. The paper includes human receptor material in a laboratory assay and behavioral experiments in mice; those are different from people reporting experiences. The paper’s stated study designs.

Does 33 times higher binding affinity establish a safe dose of THCP?

No. That ratio compares receptor binding and does not establish human dosing, product safety or a predictable experience multiplier. The original paper’s endpoints cannot answer those separate questions. The limits of the original experiment.

Tags: THCP 33 times binding affinity explained; THCP human evidence versus receptor tests